Apollo Medical Holdings reported a 51% increase in revenue for Q4 2022, reaching $294.2 million. However, the company experienced a net loss attributable to ApolloMed of $2.6 million, compared to a net income of $13.8 million in the prior-year quarter. Adjusted EBITDA increased by 54% to $23.7 million.
Total revenue increased by 51% to $294.2 million compared to the prior-year quarter.
Net loss attributable to ApolloMed was $2.6 million, compared to net income of $13.8 million in the prior-year quarter.
Adjusted EBITDA increased by 54% to $23.7 million compared to the prior-year quarter.
Capitation revenue increased by 63% to $252.9 million compared to the prior-year quarter.
ApolloMed provided guidance for the year ending December 31, 2023, with total revenue expected to be between $1.3 billion and $1.5 billion.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance